Latest Canadian Research: Cannabinoids Can Treat COVID-19 And COVID-19, And Atomization Is More Effective

                             Latest Canadian research: Cannabinoids can treat COVID-19 and COVID-19, and atomization is more effective

In a comprehensive review, a group of Canadian scientists offers interesting insights into the potential role of cannabinoids in the fight against COVID-19. The study is titled "Cannabinoids and endocannabinoid systems in patients infected with early SARS-CoV-2 and chronic COVID-19". The authors of the report are Cassidy Scott, Stefan Hall, Juan Zhou and Christian Lehmann. , published in the Journal of Clinical Medicine.

By analyzing a large amount of past research data, the report explores how components of the cannabis plant play a key role in preventing the onset of COVID-19 and mitigating its long-term effects. The findings suggest that cannabinoids, particularly those extracted from the cannabis plant, may inhibit viral entry into cells, reduce harmful oxidative stress, and suppress the often fatal immune response seen in severe cases. This study also highlights the potential role of cannabinoids in addressing various ongoing symptoms of COVID-19.

According to the study, cannabinoids show potential in preventing viral entry, alleviating oxidative stress and alleviating the cytokine storm associated with the COVID-19 virus. Research shows that specific cannabis extracts can downregulate levels of the protein acetate (ACE2) in key tissues to block viral entry into human cells. The researchers pointed out that this aspect is crucial considering that acetate protein (ACE2) is the main channel for virus entry.
The report also discusses the role of cannabinoids in resolving oxidative stress, an important factor in the pathogenesis of COVID-19. By converting free radicals into a less active form, cannabinoids like CBD can help mitigate the harmful effects of oxidative stress in severe cases of COVID-19.

According to the study, cannabinoids may also have beneficial effects on cytokine storm, a severe immune response triggered by COVID-19. Cannabinoids have been shown to be effective in reducing inflammatory cytokines, suggesting their potential in managing such immune responses.
After becoming chronic, COVID-19 is often called Long-COVID. The research reveals the potential of cannabinoids in treating ongoing symptoms of depression, anxiety, post-traumatic stress injury, insomnia, pain and loss of appetite. The endocannabinoid system is involved in various nervous system interactions, making it a target for treating these neuropsychiatric symptoms.

The study also explored the various consumption methods used by consumers, as well as the different types of cannabis products. Studies indicate that ingestion through snorting may have negative effects on patients with respiratory illnesses, negating its therapeutic effects.
"Although smoking and vaping are often the first choices for cannabis patients because they have the fastest onset of effects, the potential benefits of cannabinoid therapy may be offset by the negative respiratory health effects of smoking methods," the researchers said. Study It has been shown that vaping cannabis can cause fewer respiratory symptoms in patients than smoking it because the vaping device does not heat the cannabis to the point of combustion."

The report's authors highlighted the need for further research in this area. While preliminary findings are encouraging, they caution that they are preliminary and derived from studies that are not specific to COVID-19. Therefore, more targeted and extensive research, including clinical trials, is critical to fully understand the role and efficacy of cannabinoids in the treatment of early and post-acute SARS-CoV-2 infection. At the same time, the authors advocate for deeper research into the role of the endocannabinoid system in pharmacology and potential therapeutic applications, and urge the scientific community to explore this pathway more rigorously.

In order to promote the development of medical cannabis and CBD industries in Asia and bring new business and investment opportunities to Asia, Xinma Group will join hands with cannabis science experts from many Asian countries and global industry elites to hold the event in Bangkok, Thailand, from May 8 to 9, 2024. Asia International Cannabis Business Summit & Expo.

Wetchat/whatsapp: 15818383206(Edith sun)